Irreversible visual loss after use of Paclitaxel

Amigo, Maria Helena Lopes; Falabella, Paulo; Bettarello, Ângela; Ghirelli, Wagner

doi:10.5935/0034-7280.20150053

Cited by 6 publications

(4 citation statements)

References 5 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8 A case of irreversible paclitaxel induced maculopathy with CME has been previously reported with the authors proposing paclitaxel toxicity resulted in permanent cell damage. 9 To the best of our knowledge, we report the first case of paclitaxel induced maculopathy in the absence of CME.…”

Section: Discussionmentioning

confidence: 82%

“…In the absence of an alternative explanation, paclitaxel phototoxic maculopathy was considered the most likely cause as paclitaxel is known to induce maculopathy and the inferior distribution of maculopathy corresponded with the endoillumination probe entering superiorly. 4 , 5 , 6 , 7 , 8 , 9 …”

Section: Discussionmentioning

confidence: 99%

“…Cases of maculopathy caused by paclitaxel have previously been reported, notably featuring cystoid macular edema (CME). 4 , 5 , 6 , 7 , 8 , 9 To the best of our knowledge, we report the first case of suspected paclitaxel induced phototoxic maculopathy secondary to endoillumination.…”

Section: Introductionmentioning

confidence: 86%

See 2 more Smart Citations

Paclitaxel may be a risk factor for retinal phototoxicity

Malcolm

Wong

Ching

et al. 2022

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Purpose To report the first case, to our knowledge, of suspected paclitaxel induced phototoxic maculopathy following vitrectomy surgery. Observations A 62-year-old phakic female receiving paclitaxel therapy for ovarian carcinoma presented with a best corrected visual acuity (BCVA) of 20/40 OD with an epiretinal membrane (ERM) and lamellar macular hole on spectral domain optical coherence tomography (SD-OCT). The patient underwent an uneventful pars plana vitrectomy with ERM peel using standard illumination and vitrectomy settings. Membrane Blue Dual (DORC, Netherlands) was used to stain the ERM. Two weeks post-operatively, the patient presented with a reduced BCVA of 20/200 in the operated eye. Fluorescein and indocyanine green angiography revealed right sided patchy hypofluorescence and hyperfluorescence secondary to retinal pigment epithelium changes with intact choroidal and retinal vasculature. SD-OCT and fundoscopy showed right sided loss of ellipsoid layer, increased reflectivity within the retinal pigmented epithelium and subretinal fibrosis without cystoid macular edema. Four months post-operatively her vision had stabilized to 20/160; unfortunately, the patient was palliated a month later due to ovarian carcinoma progression. Conclusions A number of drugs are known to increase photosensitivity to solar and artificial forms of radiation. Paclitaxel use has been widely reported to cause dermatological photosensitivity. We report a case of suspected paclitaxel induced phototoxic maculopathy following endoillumination during vitrectomy surgery.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel may be a risk factor for retinal phototoxicity

Malcolm

Wong

Ching

et al. 2022

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

show abstract

“…Given that these medications had been completed more than 4 years prior to her presentation, we believe that they were unlikely to be the cause of her corneal findings. And, while retinal and optic nerve toxicities are known adverse effects of paclitaxel, we are not aware of corneal toxicity as a reported side effect [ 23 – 27 ]. Herceptin and related drugs, however, have been associated with adverse effects on the anterior segment with dry eye, epiphora, blurred vision, and conjunctivitis being the most common [ 12 , 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Subepithelial Corneal Deposits Associated with Exemestane

Amireskandari

Nguyen

Hinkle

et al. 2020

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

This is a case report of corneal deposits noted in a 69-year-old female patient taking the aromatase inhibitor, exemestane, after undergoing a mastectomy and chemotherapy for breast cancer. The patient presented to our eye clinic for a new-onset floater in one eye, and bilateral subepithelial opacities were found incidentally on exam. The patient completed a 5-year course of the medication shortly after her initial visit with us and was noted to have a slight improvement in the density of the opacities on a follow-up visit 3 months later. We believe these corneal changes were most likely secondary to exemestane. The effect of aromatase inhibitors on the eye deserves further exploration as an increasing number of patients are prescribed these medications.

show abstract